Literature DB >> 24085500

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.

Judith E Kalinyak1, Wendie A Berg, Kathy Schilling, Kathleen S Madsen, Deepa Narayanan, Marie Tartar.   

Abstract

PURPOSE: To compare the performance characteristics of positron emission mammography (PEM) with those of whole-body PET (WBPET) and PET/CT in women with newly diagnosed breast cancer.
METHODS: A total of 178 women consented to PEM for presurgical planning in an IRB-approved protocol and also underwent either WBPET (n = 69) or PET/CT (n = 109) imaging, as per usual care at three centers. Tumor detection sensitivity, positive predictive values, and (18)F-fluorodeoxyglucose (FDG) uptake were compared between the modalities. The effects of tumor size, type, and grade on detection were examined. The chi-squared or Fisher's exact tests were used to compare distributions between groups, and McNemar's test was used to compare distributions for paired data within subject groups, i.e. PEM versus WBPET or PEM versus PET/CT.
RESULTS: The mean age of the women was 59 ± 12 years (median 60 years, range 26-89 years), with a mean invasive index tumor size of 1.6 ± 0.8 cm (median 1.5 cm, range 0.5-4.0 cm). PEM detected more index tumors (61/66, 92%) than WBPET (37/66, 56%; p < 0.001) or PET/CT (95/109, 87% vs. 104/109, 95% for PEM; p < 0.029). Sensitivity for the detection of additional ipsilateral malignancies was also greater with PEM (7/15, 47%) than with WBPET (1/15, 6.7%; p = 0.014) or PET/CT (3/23, 13% vs. 13/23, 57% for PEM; p = 0.003). Index tumor detection decreased with decreasing invasive tumor size for both WBPET (p = 0.002) and PET/CT (p < 0.001); PEM was not significantly affected (p = 0.20). FDG uptake, quantified in terms of maximum PEM uptake value, was lowest in ductal carcinoma in situ (median 1.5, range 0.7-3.0) and invasive lobular carcinoma (median 1.5, range 0.7-3.4), and highest in grade III invasive ductal carcinoma (median 3.1, range 1.4-12.9).
CONCLUSION: PEM was more sensitive than either WBPET or PET/CT in showing index and additional ipsilateral breast tumors and remained highly sensitive for tumors smaller than 1 cm.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085500     DOI: 10.1007/s00259-013-2553-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

1.  Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard.

Authors:  Francesco Sardanelli; Gian M Giuseppetti; Pietro Panizza; Massimo Bazzocchi; Alfonso Fausto; Giovanni Simonetti; Vincenzo Lattanzio; Alessandro Del Maschio
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

2.  Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast.

Authors:  Wendie A Berg; Kathleen S Madsen; Kathy Schilling; Marie Tartar; Etta D Pisano; Linda Hovanessian Larsen; Deepa Narayanan; Al Ozonoff; Joel P Miller; Judith E Kalinyak
Journal:  Radiology       Date:  2010-11-12       Impact factor: 11.105

3.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

5.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

6.  Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial.

Authors:  N H G M Peters; S van Esser; M A A J van den Bosch; R K Storm; P W Plaisier; T van Dalen; S C E Diepstraten; T Weits; P J Westenend; G Stapper; M A Fernandez-Gallardo; I H M Borel Rinkes; R van Hillegersberg; W P Th M Mali; P H M Peeters
Journal:  Eur J Cancer       Date:  2010-12-30       Impact factor: 9.162

7.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

8.  MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results.

Authors:  Steven G Lee; Susan G Orel; Irene J Woo; Eva Cruz-Jove; Mary E Putt; Lawrence J Solin; Brian J Czerniecki; Mitchell D Schnall
Journal:  Radiology       Date:  2003-01-31       Impact factor: 11.105

9.  Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.

Authors:  William B Eubank; David Mankoff; Mallar Bhattacharya; Julie Gralow; Hannah Linden; Georgiana Ellis; Skyler Lindsley; Mary Austin-Seymour; Robert Livingston
Journal:  AJR Am J Roentgenol       Date:  2004-08       Impact factor: 3.959

10.  The relationship between FDG uptake in PET scans and biological behavior in breast cancer.

Authors:  Wataru Shimoda; Mitsuhiro Hayashi; Koji Murakami; Tetsunari Oyama; Masakatsu Sunagawa
Journal:  Breast Cancer       Date:  2007       Impact factor: 4.239

View more
  19 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

Review 2.  Use of Breast-Specific PET Scanners and Comparison with MR Imaging.

Authors:  Deepa Narayanan; Wendie A Berg
Journal:  Magn Reson Imaging Clin N Am       Date:  2018-05       Impact factor: 2.266

3.  Breast cancer: a new imaging approach as an addition to existing guidelines.

Authors:  Monique D Dorrius; Erik F J de Vries; Riemer H J A Slart; Andor W J M Glaudemans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-12       Impact factor: 9.236

4.  Impact of Using Uniform Attenuation Coefficients for Heterogeneously Dense Breasts in a Dedicated Breast PET/X-ray Scanner.

Authors:  Lawrence R MacDonald; Joseph Y Lo; Gregory M Sturgeon; Chengeng Zeng; Robert L Harrison; Paul E Kinahan; William Paul Segars
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-04-29

5.  [Molecular breast imaging. An update].

Authors:  K Pinker; T H Helbich; H Magometschnigg; B Fueger; P Baltzer
Journal:  Radiologe       Date:  2014-03       Impact factor: 0.635

6.  Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography?

Authors:  Almir G V Bitencourt; Eduardo N P Lima; Bruna R C Macedo; Jorge L F A Conrado; Elvira F Marques; Rubens Chojniak
Journal:  Eur Radiol       Date:  2016-09-02       Impact factor: 5.315

Review 7.  Ultrasound Imaging Technologies for Breast Cancer Detection and Management: A Review.

Authors:  Rongrong Guo; Guolan Lu; Binjie Qin; Baowei Fei
Journal:  Ultrasound Med Biol       Date:  2017-10-26       Impact factor: 2.998

8.  Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Authors:  David Groheux; Mohamed Majdoub; Florent Tixier; Catherine Cheze Le Rest; Antoine Martineau; Pascal Merlet; Marc Espié; Anne de Roquancourt; Elif Hindié; Mathieu Hatt; Dimitris Visvikis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-04       Impact factor: 9.236

Review 9.  Main controversies in breast cancer.

Authors:  Stephane Zervoudis; George Iatrakis; Eirini Tomara; Anastasia Bothou; George Papadopoulos; George Tsakiris
Journal:  World J Clin Oncol       Date:  2014-08-10

10.  Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.

Authors:  Kazuhiro Kitajima; Koya Nakatani; Kazushige Yamaguchi; Masatoyo Nakajo; Atsushi Tani; Mana Ishibashi; Keiko Hosoya; Takahiro Morita; Takayuki Kinoshita; Hayato Kaida; Yasuo Miyoshi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.